Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Andreas (NOR-Solidarity)
 
NCT04321616
RCTremdesivirCOVID 19 all comerslow
43/58 ongoing
    Norwegian NOR study (remdesivir)
     
    NCT04321616
    RCTremdesivirstandard of careCOVID 19 all comerssome concern
    43/58 no results
      Chang Chen et al.
       
      ChiCTR2000030254
      RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
      120/120 inconclusive
      • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      ELACOI (Standard of care)
       
      NCT04252885
      RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
      16/7 inconclusive
        Lou (FAVIPIRAVIR)
         
        ChiCTR2000029544
        RCTfavipiravir standard of careCOVID 19 all comerssome concern
        10/10 inconclusive
        • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
        NCT04310228-FAVI (Zhao)
         
        ChiCTR2000030894
        RCTfavipiravir tocilizumab COVID 19 all comerssome concern
        -/- inconclusive
        • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        7 studies excluded by filtering options (3 RCT / 4 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).